| Cell therapy for type 2 diabetes: is it desirable and can we get it? | |
| | |
MedLine Citation:
|
PMID: 18834449 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The functional mass of beta-cells is decreased in type 2 diabetes. Replacing missing beta-cells or triggering their regeneration may thus allow for improved treatment of type 2 diabetes, to the extent that this is combined with therapy for improved insulin sensitivity. Although progress has been made in deriving beta-cell-like cells from stem or precursor cells in vitro, these cannot yet be obtained in sufficient quantities or well enough differentiated to envisage their therapeutic use in beta-cell replacement therapy. Likewise, our very limited understanding of beta-cell regeneration in adult man does not yet allow for development of a valid strategy for kick-starting such a process in individuals with type 2 diabetes, whether by bona fide neogenesis or self-replication of existing beta-cells. Regardless of how beta-cell mass is restored in type 2 diabetes, it will be important to prevent any renewed decrease thereafter. Current understanding suggests that islet inflammation as well as signals from (insulin-resistant/inflamed) adipose tissue and skeletal muscle contribute towards decreased beta-cell mass in type 2 diabetes. It will likely be important to protect newly formed or implanted beta-cells from these negative influences to ensure their long-term survival. |
| | |
Authors:
|
P A Halban |
Related Documents
:
|
3159609 - Chlorozocin. a diabetogenic analogue of streptozocin with dissimilar mechanisms of acti... 8627419 - Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human... 3514609 - Inhibition of post-translational modification and surface expression of a melanoma-asso... 10194529 - Beta-cell gene expression and functional characterisation of the human insulinoma cell ... 8250289 - Temporal coincidence of the appearance of elongated spermatids and of histochemical rea... 9332729 - Transforming growth factor-beta protects human hnt cells from degeneration induced by b... 10636889 - Up-regulation of multidrug resistance p-glycoprotein via nuclear factor-kappab activati... 422679 - Analysis of the significance of a periodic, cell size-controlled doubling in rates of m... 16510219 - Cardiac metastasis after squamous cell carcinoma of the oral cavity: case report. |
Publication Detail:
|
Type: Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 10 Suppl 4 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-06 Completed Date: 2008-12-09 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 205-11 Citation Subset: IM |
Affiliation:
|
Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland. philippe.halban@medecine.unige.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diabetes Mellitus, Type 2 / physiopathology, therapy* Female History, 18th Century History, 19th Century History, 20th Century History, 21st Century Humans Insulin Resistance / physiology* Islets of Langerhans / cytology*, physiology Male Stem Cell Transplantation / methods*, trends Tissue Therapy / methods*, trends |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Insulitis in type 2 diabetes.
Next Document: Antenatal syphilis serology in pregnant women and follow-up of their infants in northern Italy.